Sea Moss for Psoriasis: Why This Is a Th17 Problem, Not a Th2 Problem

Psoriasis and eczema look similar to the untrained eye — both produce inflamed, uncomfortable skin — but they're driven by completely different immune mechanisms, and confusing them leads to misguided treatment approaches.

Th1/Th17 vs. Th2: Why the Distinction Matters

Eczema is Th2-driven: IgE, mast cells, histamine, IL-4, IL-13. Antihistamines help because histamine is the primary mediator. Psoriasis is Th1/Th17-driven: TNF-α, IL-17, IL-23 cause keratinocytes (skin cells) to proliferate at 7x the normal rate, creating the characteristic thick plaques. Antihistamines don't help psoriasis at all — different cytokines. This is why the most effective psoriasis biologics specifically target TNF-α (adalimumab), IL-17 (secukinumab), or IL-23 (guselkumab) rather than histamine pathways.

What Fucoidan Does in the Psoriasis Context

Fucoidan has demonstrated TNF-α and IL-6 suppression in multiple in vitro studies, and NF-κB inhibition — the master switch that drives inflammatory cytokine production including IL-17. This is mechanistically aligned with psoriasis's driver cytokines. The concentrations in cell studies and the amounts achievable through dietary sea moss consumption differ substantially — no RCTs in psoriasis patients exist. But the mechanism is correctly targeted in a way that eczema's IgE/histamine pathway is not.

Zinc and Keratinocyte Regulation

Psoriasis involves runaway keratinocyte proliferation. Zinc regulates keratinocyte cell cycle progression through zinc-dependent transcription factors. Multiple observational studies show lower serum zinc in psoriasis patients versus controls, and zinc serum levels correlate inversely with psoriasis severity scores. Sea moss provides 0.1-0.3mg zinc per tablespoon — dietary support, not the 30-50mg/day used in therapeutic zinc trials. But consistent dietary zinc support maintains the baseline regulatory function zinc provides.